Clinical comparability of marketed formulations of botulinum toxin.
about
Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical PracticeSystematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Blepharospasm and Hemifacial SpasmRepeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunctionDiffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications.Dosing, efficacy and safety plus the use of computerized photography for botulinum toxins type A for upper facial lines.Temporal characteristics of botulinum neurotoxin therapy.Botulinum toxin type A products are not interchangeable: a review of the evidence.Botulinum toxin: bioweapon & magic drugBotulinum toxin in the management of blepharospasm: current evidence and recent developmentsDysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study.Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine.Botulinum toxin type A for the treatment of migraine.Botulinum neurotoxin - from laboratory to bedside.The management of cervical dystonia.Botulinum neurotoxin type A in facial aesthetics.Efficacy of Onabotulinum Toxin A (Botox) versus Abobotulinum Toxin A (Dysport) Using a Conversion Factor (1 : 2.5) in Treatment of Primary Palmar HyperhidrosisMedium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder.Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review.Botulinum toxin for the treatment of movement disorders.Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer.Diffusion of botulinum toxinsLong-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.Use of botulinum toxin for voiding dysfunction.Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity.Changes in Management of Poorly Compliant Bladder in Botulinum Toxin A Era.Treatment of Primary Axillary Hyperhidrosis by Fractional Microneedle Radiofrequency: Is it Still Effective after Long-term Follow-up?Adverse events associated with botulinum toxin injection: a multidepartment, retrospective study of 5310 treatments administered to 1819 patients.Effect of botulinum toxin A on vasoconstriction and sympathetic neurotransmitters in a murine random pattern skin flap model.Fractionated microneedle radiofrequency for treatment of primary axillary hyperhidrosis: A sham control study.Botulinum toxin injection for post-stroke spasticity.Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal.Retrospective evaluation of the dose equivalence of Botox® and Dysport® in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story
P2860
Q26766728-CCA3F39E-B434-4247-BBBF-B815DBA837C1Q26777217-77B40624-151D-451C-9E7A-3D0302A19359Q28304077-A5C16892-9BE6-40A5-899E-7BC245EE80CAQ33299849-3BE15DA7-90BB-4611-B887-65F1CB8CC5E5Q33530904-9B17E36E-2610-47E5-BC64-0789CFF83553Q33740588-FC6A71EC-397F-4E68-B9AD-0B40CBDE1CE3Q34352934-BD6533A2-30B6-499A-A7BA-A92449C8DD7FQ34530009-2BFFDB48-5A7D-4F67-9A55-D122B377D3A9Q35168607-F0454D85-A07C-4CC6-8295-0F81C8363AD1Q35175351-6989A588-8416-4F63-9551-273137AD284BQ35681903-C8AEB8CF-536C-4DE1-A1B7-D395F08B84D4Q36488226-6294B707-5A7A-4A31-B530-66CF43B41011Q36511588-3A386A39-F558-4785-A2E6-97920D0D9B6BQ36719664-3E99DF73-7962-4BE8-8936-FA7C85A51974Q36828130-740F78BD-770C-4A33-9A8A-7613A7211C1BQ37286003-12ACF769-70BD-41FC-BA04-89016F15F1BEQ37514596-E4043741-8D59-44C8-80F9-762A1CA9B4CBQ37987484-BC3A4277-613C-436B-8BA5-F394CAFDDA0EQ38015772-BA286D6A-C0E1-4393-BBCE-A82C38AD9921Q38080776-9A64C1F1-B096-449F-8712-A7C1324509D6Q38084574-E7865D66-0FA4-43AE-8172-5009E2CAAE38Q38120775-304DA952-5D80-487E-A6F8-6DA328A6612FQ38679555-3308C3FC-53DE-4A8C-B6BA-1475754E1897Q38826378-A24DA60D-32C6-4302-9BF8-7308BA435B5CQ39196977-05D8BC4D-F999-4435-95C0-882A0E0E97F0Q39423373-032499E0-9E39-4C2E-8A7A-54608231DA86Q39778503-290A8E47-48E3-40E0-A4DD-CC05DB58CEB3Q43539225-C6DBC1A0-038A-44B3-BE2C-656B561E66EAQ48133611-3C9578AB-1832-4831-962C-1C1C4B72691AQ51763215-8E9B301E-911C-4126-ACD4-4D744DD0D36CQ53596198-0092DF80-C735-4107-8122-D85C071B48C1Q55039946-921EBE3A-AA11-41D1-8470-B5DF2D2D4291Q59153415-2EC84BE1-0717-421D-8938-9E023CA1DC15
P2860
Clinical comparability of marketed formulations of botulinum toxin.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Clinical comparability of marketed formulations of botulinum toxin.
@ast
Clinical comparability of marketed formulations of botulinum toxin.
@en
type
label
Clinical comparability of marketed formulations of botulinum toxin.
@ast
Clinical comparability of marketed formulations of botulinum toxin.
@en
prefLabel
Clinical comparability of marketed formulations of botulinum toxin.
@ast
Clinical comparability of marketed formulations of botulinum toxin.
@en
P356
P1433
P1476
Clinical comparability of marketed formulations of botulinum toxin.
@en
P2093
Joaquim J Ferreira
João Costa
P2860
P304
P356
10.1002/MDS.20066
P407
P478
19 Suppl 8
P577
2004-03-01T00:00:00Z